Philogen SpA's "idea is to stop [melanoma] when you have metastases, but only at the skin," co-founder Dario Neri told BioWorld Today, as his firm launched its pivotal trial in about 200 patients testing Darleukin against stage IIIb/c disease, which "almost invariably" worsens to often-fatal stage IV within two years.